BOLD Boundless Bio

-

Boundless Bio Reported Earnings

Friday, August 7, 2026 · 12:00 AM ET

Boundless Bio (BOLD) reported a loss of $1.06 per share on revenue of $0.00 million for the second quarter ended June 2026. .

Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients.

Earnings Whisper Grade
Power Rating
Reported Earnings
($1.06)
Earnings Whisper®
Consensus Estimate
Earnings Surprise
Earnings Growth-51.4 %
Reported Revenue
Revenue Estimate
Revenue Surprise
Revenue Growth